Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab

PHASE4CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

July 31, 2014

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

aflibercept 2mg

Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Vista Klinik

OTHER